Analysts Expect West Pharmaceutical Services, Inc. (NYSE:WST) Will Post Earnings of $0.53 Per Share
Equities analysts expect West Pharmaceutical Services, Inc. (NYSE:WST) to report earnings of $0.53 per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for West Pharmaceutical Services’ earnings, with estimates ranging from $0.53 to $0.54. West Pharmaceutical Services also posted earnings of $0.53 per share during the same quarter last year. The business is scheduled to report its next earnings report on Thursday, October 26th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full year earnings of $2.69 per share for the current year, with EPS estimates ranging from $2.66 to $2.72. For the next year, analysts anticipate that the firm will post earnings of $2.91 per share, with EPS estimates ranging from $2.80 to $2.97. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $397.60 million during the quarter, compared to analyst estimates of $406 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 EPS.
Several research analysts recently commented on WST shares. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Friday, June 23rd. BidaskClub cut West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $90.00 price target on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $90.18.
Shares of West Pharmaceutical Services (NYSE:WST) traded down 0.40% during midday trading on Wednesday, hitting $86.36. The stock had a trading volume of 358,021 shares. The company has a market capitalization of $6.39 billion, a PE ratio of 37.06 and a beta of 1.10. West Pharmaceutical Services has a one year low of $70.17 and a one year high of $99.91. The firm’s 50-day moving average is $94.28 and its 200 day moving average is $88.75.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be given a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.65%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 22.22%.
In other news, CFO William J. Federici sold 54,996 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $95.45, for a total value of $5,249,368.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.90% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Burt Wealth Advisors boosted its stake in West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 1,927 shares during the last quarter. Harfst & Associates Inc. acquired a new stake in West Pharmaceutical Services during the first quarter worth about $186,000. Tyers Asset Management LLC boosted its stake in West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock worth $201,000 after buying an additional 368 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in West Pharmaceutical Services by 1.6% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 40 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT acquired a new stake in West Pharmaceutical Services during the second quarter worth about $212,000. 91.35% of the stock is owned by institutional investors.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.